瑞舒伐他汀对早期糖尿病肾病患者外周血内血清瘦素、炎性因子、血脂水平及肾功能的影响

摘要/Abstract

摘要： 目的观察瑞舒伐他汀对早期糖尿病肾病患者外周血内血清瘦素、炎性因子、血脂水平及肾功能的影响。方法选取80例糖尿病肾病（DN）患者，作为研究对象，随机分为对照组（40例）和观察组（40例），两组患者均进行常规DN治疗。观察组在常规治疗基础上加用瑞舒伐他汀10 mg?d-1，两组患者均持续治疗12周。比较两组患者治疗前后血清瘦素、炎性因子、血脂水平及肾功能变化。结果治疗后观察组血清瘦素、C反应蛋白（hs-CRP）、肿瘤坏死因子-ɑ（TNF-ɑ）、白细胞介素6(IL-6)、甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白（LDL）、血尿素氮(BUN)、血肌酐(Scr)、24 h尿微量白蛋白排泄率（UAER）水平显著低于对照组及同组治疗前（P<0.05）；高密度脂蛋白（HDL）、肾小球滤过率（GFR）显著高于对照组及同组治疗前（P<0.05）。结论常规治疗基础上加用瑞舒伐他汀治疗DN患者，在有效降低外周血内血清瘦素及炎性因子水平的同时，也可显著降低血脂水平，改善肾功能，具有一定临床价值。

关键词: 瑞舒伐他汀, 糖尿病肾病, 瘦素, 炎性因子, 血脂, 肾功能

Abstract: Objective To observe the effect of rosuvastatin on serum leptin, inflammatory factors, blood lipid and renal function in patients with early diabetic nephropathy. Methods 80 cases of diabetic nephropathy (DN) patients were selected and randomly divided into control group(40 cases) and observation group(40 cases). Two groups were treated with conventional treatment. The patients in the observation group were given 10 mg rosuvastatin every day on the basis of the conventional treatment. Two groups of patients were treated for 12 weeks. The changes of serum leptin, inflammatory factor, blood lipid and renal function were compared between the two groups before and after treatment. Results After treatment, the serum leptin, C reactive protein (hs-CRP), tumor necrosis factor-ɑ(TNF-ɑ), interleukin 6 (IL-6), triglyceride (TG), total cholesterol (TC), low density lipoprotein (LDL), blood urea nitrogen (BUN), serum creatinine (Scr) and 24 h urinary albumin excretion rate (UAER) level of the observation group were significantly lower than those of the control group and the same group before treatment (P<0.05). The high density lipoprotein (HDL) and glomerular filtration rate (GFR) of the observation group were significantly higher than those of the control group and the same group before treatment (P<0.05). Conclusion Besides decreasing the levels of serum leptin and inflammatory factors, rosuvastatin can significantly reduce the blood lipid level, and improve renal function, which have a certain clinical value for the diagnosis and treatment of DN.

Key words: rosuvastatin, diabetic nephropathy, leptin, inflammatory factor, blood lipid, renal function

中图分类号:

R969.4

张蓓慧. 瑞舒伐他汀对早期糖尿病肾病患者外周血内血清瘦素、炎性因子、血脂水平及肾功能的影响[J]. 中国药物警戒, 2017, 14(6): 338-340.

ZHANG Bei-hui. Effect of Rosuvastatin on Serum Leptin, Inflammatory Factors, Blood Lipid and Renal Function in Patients with Early Diabetic Nephropathy[J]. Chinese Journal of Pharmacovigilance, 2017, 14(6): 338-340.

参考文献

[1] 肖艳春, 闻春艳. 诺和龙与阿托伐他汀联合治疗糖尿病肾病的临床疗效[J]. 中国老年学杂志, 2016, 36(11):2672-2673.
[2] 李莎, 王芳, 唐亮, 等. 阿托伐他汀对糖尿病肾病患者肾脏保护作用的Meta分析[J]. 中国药房, 2014, 25(40): 3752-3755.
[3] 曾婷婷. 190例他汀类降脂药品不良反应病例分析[J]. 中国药物警戒, 2013, 10(2): 96-100.
[4] 侯茜, 胡可, 梁捷予, 等. 多项指标联合检测对早期糖尿病肾病的临床价值[J]. 中国现代医学杂志, 2014, 24(30): 49-52.
[5] Huang Y Q, Gou R, Diao Y S, et al. Charlson comorbidity index helps predict the risk of mortality for patients with type 2 diabetic nephropathy[J]. Journal of Zhejiang University.science.b, 2014, 15(1): 58-66.
[6] 刘芝, 杜玉君, 孟帮柱, 等. 早期糖尿病肾病相关因素分析及其在传统医药临床试验设计中的应用[J]. 中药药理与临床, 2015, 31(1): 224-228.
[7] 李颖. 不同血液透析方式对慢性肾功能衰竭血液透析患者β_2-微球蛋白和瘦素清除率的影响[J]. 现代预防医学, 2012, 39(14): 3657-3658.
[8] 张新, 王鲲, 秦陆兵. 早期糖尿病肾病患者口服阿托伐他汀后血清瘦素水平及肾功能变化[J]. 山东医药, 2015, 55(23): 33-35.
[9] 万青松, 谢红萍, 杨波, 等. 阿托伐他汀钙对2型糖尿病肾病患者瘦素的影响[J]. 实用医学杂志, 2014, 30(22): 3655-3657.
[10] 王颖, 朱铁虹, 佟俊旺, 等. 糖尿病慢性肾脏疾病患者血清瘦素和血脂水平的变化及其临床意义的研究[J]. 中国糖尿病杂志, 2015, 23(8): 711-713.
[11] 何煜, 张琰, 廖婷婷, 等. 老年早期糖尿病肾病患者血清胱抑素C与氧化应激的相关性[J]. 中国老年学杂志, 2014, 34(3): 594-596.
[12] Zheng X Y, Zhu S Y, Zhou Y D, et al. Amelioration of Diabetic Nephropathy in Rats by Resveratrol:Involvement of Anti-Inflammatory Effect[J]. Journal of Chinese Pharmaceutical Sciences, 2014, 49(11): 919-924.
[13] 陶松青, 陈严文, 李海涛, 等. 瑞舒伐他汀治疗临床期糖尿病肾病疗效观察[J]. 现代中西医结合杂志, 2014, 23(31): 3441-3443.
[14] Ying W, Chen L M, Liu M L. Microvesicles and diabetic complications — novel mediators, potential biomarkers and therapeutic targets[J]. Acta Pharmacologica Sinica, 2014, 35(4): 433-443.
[15] 郭慧, 刘良专, 刘江华. 降脂通络软胶囊联合瑞舒伐他汀对2型糖尿病合并高脂血症患者效果观察[J]. 重庆医学, 2015,44(24): 3348-3349.
[16] 丁玲, 胡毅, 袁野. 阿托伐他汀对早期糖尿病肾病患者血脂、炎性因子及肾功能的影响[J]. 中国药房, 2015, 26(15): 2035-2037.
[17] 李晓花. 阿托伐他汀对早期糖尿病肾病临床治疗的影响[J]. 基层医学论坛, 2016, 20(4): 542-544.
[18] 林浩海, 秦超, 程道宾, 等. 阿托伐他汀强化治疗对脑血管介入诊疗术后造影剂肾病的影响[J]. 中国药物警戒, 2015, 12(5): 267-270.
[19] 宋艳, 胡晓丽. 瑞舒伐他汀对早期糖尿病肾病患者血清C反应蛋白和炎性细胞因子IL-1、IL-6表达的影响[J]. 中华临床医师杂志:电子版, 2011, 5(13): 3716-3720.